<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737866</url>
  </required_header>
  <id_info>
    <org_study_id>20080676</org_study_id>
    <nct_id>NCT01737866</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency</brief_title>
  <official_title>An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, open-label study in subjects with normal renal function and subjects with various
      degrees of renal insufficiency, including patients with end-stage renal disease (ESRD)
      requiring hemodialysis. The primary objective is to evaluate the single-dose PK of AMG 423 in
      subjects with various degrees of renal insufficiency, including patients with end-stage renal
      disease requiring hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMG 423 Pharmacokinetic Parameters</measure>
    <time_frame>Twenty time points, up to eight days</time_frame>
    <description>Part A and Part B: Total AMG 423 pharmacokinetic parameters including area under the plasma concentration time curve (AUC) from time 0 to the time of the last quantifiable sample (AUC0-t) and maximum observed plasma concentration after dosing (Cmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Total AMG 423 PK Parameters</measure>
    <time_frame>Twenty time points, up to eight days</time_frame>
    <description>Total AMG 423 pharmacokinetic parameters including but not limited to terminal phase half life (t1/2) and time of maximum AMG 423 plasma concentration (tmax), AUC from time 0 to infinity (AUCinf) and apparent plasma clearance (CL/F) for Part A and Part B;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMG 423 Dialysis Clearance</measure>
    <time_frame>Hours 4, 5, 6, 7 &amp; 8 post-dose</time_frame>
    <description>AMG 423 dialysis clearance (CLd) for ESRD subjects in Part A;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMG 423 Metabolites</measure>
    <time_frame>Twenty time points, up to eight days</time_frame>
    <description>AMG 423 metabolites (M3 and M4) pharmacokinetic parameters including but not limited to AUC0-t, AUCinf, AUC metabolite to parent ratios, Cmax, tmax and t1/2, if appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 46 days, including a 28 day screening period</time_frame>
    <description>Secondary safety endpoints are subject incidence of adverse events and clinically significant changes in vital signs, physical examinations, clinical laboratory tests and ECGs.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End Stage Renal Diseas (ESRD) requiring hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal renal function (eGFR &gt;or = 80mL/min/1.73m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal renal function (eGFR &gt;or = 80mL/min/1.73m^2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 423</intervention_name>
    <description>omecamtiv mecarbil</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women â‰¥18 years of age

          -  Laboratory test values (clinical chemistry and hematology)within normal limits, (other
             than test values out of the normal range for subjects with CKD [groups 1 and 3 through
             5]), or clinically acceptable to the investigator and sponsor at screening and day -3

          -  Free of any clinically significant disease or condition(s) (other than that consistent
             with CKD for subjects in groups 1 and 3 through 5) that require a physician's care
             and/or would interfere with the evaluations, procedures, or participation in the study
             per the investigator's discretion;

        Exclusion Criteria:

          -  Subjects whose second MDRD eGFR result during the screening period is not within 10%
             of the first eGFR result

          -  Subjects who have received a functioning renal transplant within the past year

          -  Subjects with ESRD who do not have a functioning hemodialysis access

          -  Subjects with hemodynamic instability during hemodialysis

          -  Subjects whose renal insufficiency is due to active autoimmune renal disease

          -  Subjects with renal insufficiency or ESRD requiring hemodialysis and Troponin I &gt;
             upper limit of normal (ULN) at screening or day -3

          -  Subjects with history of heart disease or unstable angina within the last 3 months

          -  Subjects with uncontrolled diabetes (Hb1Ac &gt; 8%) and/or subjects who are able but
             unwilling to adhere to the required fasting intervals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart, Failure, Renal, Insufficiency, Cardiac, Kidney, Hemodialysis, Impairment, omecamtiv mecarbil, cardiac myosin activator, CK-1827452</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

